A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of APD334 in Patients with Moderately to Severely Active Ulcerative Colitis

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of APD334 in Patients with Moderately to Severely Active Ulcerative Colitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Etrasimod (Primary)
  • Indications Ulcerative colitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 06 Sep 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2017.
    • 07 Aug 2017 According to an Arena Pharmaceuticals media release, data readout from the study is expected around year-end 2017 to Q1 2018.
    • 11 Mar 2017 This trial has been completed in the Czech Republic.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top